{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,3]],"date-time":"2026-03-03T15:24:41Z","timestamp":1772551481255,"version":"3.50.1"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,6,11]],"date-time":"2019-06-11T00:00:00Z","timestamp":1560211200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2019,6,11]],"date-time":"2019-06-11T00:00:00Z","timestamp":1560211200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100005614","name":"Biogen","doi-asserted-by":"publisher","award":["Unrestricted investigator trial grant"],"award-info":[{"award-number":["Unrestricted investigator trial grant"]}],"id":[{"id":"10.13039\/100005614","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005614","name":"Biogen","doi-asserted-by":"publisher","award":["no number available"],"award-info":[{"award-number":["no number available"]}],"id":[{"id":"10.13039\/100005614","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["PharmacoEconomics Open"],"published-print":{"date-parts":[[2020,3]]},"DOI":"10.1007\/s41669-019-0150-3","type":"journal-article","created":{"date-parts":[[2019,6,11]],"date-time":"2019-06-11T13:04:01Z","timestamp":1560258241000},"page":"91-103","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Healthcare, Sickness Absence, and Disability Pension Cost Trajectories in the First 5 Years After Diagnosis with Multiple Sclerosis: A Prospective Register-Based Cohort Study in Sweden"],"prefix":"10.1007","volume":"4","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2578-1865","authenticated-orcid":false,"given":"Korinna","family":"Karampampa","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hanna","family":"Gyllensten","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fei","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chantelle","family":"Murley","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emilie","family":"Friberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jan","family":"Hillert","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kristina","family":"Alexanderson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,6,11]]},"reference":[{"key":"150_CR1","doi-asserted-by":"publisher","first-page":"327","DOI":"10.3350\/cmh.2014.20.4.327","volume":"20","author":"C Jo","year":"2014","unstructured":"Jo C. Cost-of-illness studies: concepts, scopes, and methods. Clin Mol Hepatol. 2014;20:327\u201337.","journal-title":"Clin Mol Hepatol"},{"key":"150_CR2","doi-asserted-by":"publisher","first-page":"e108599","DOI":"10.1371\/journal.pone.0108599","volume":"9","author":"C Ahlgren","year":"2014","unstructured":"Ahlgren C, Oden A, Lycke J. High nationwide incidence of multiple sclerosis in Sweden. PLoS One. 2014;9:e108599.","journal-title":"PLoS One"},{"key":"150_CR3","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1007\/s10198-017-0894-6","volume":"19","author":"H Gyllensten","year":"2017","unstructured":"Gyllensten H, Wiberg M, Alexanderson K, et al. Costs of illness of multiple sclerosis in Sweden: a population-based register study of people of working age. Eur J Health Econ. 2017;19:435\u201346.","journal-title":"Eur J Health Econ"},{"key":"150_CR4","doi-asserted-by":"publisher","first-page":"e0159129","DOI":"10.1371\/journal.pone.0159129","volume":"11","author":"O Ernstsson","year":"2016","unstructured":"Ernstsson O, Gyllensten H, Alexanderson K, et al. Cost of illness of multiple sclerosis\u2014a systematic review. PLoS One. 2016;11:e0159129.","journal-title":"PLoS One"},{"key":"150_CR5","first-page":"205521731878335","volume":"4","author":"H Gyllensten","year":"2018","unstructured":"Gyllensten H, Kavaliunas A, Alexanderson K, et al. Costs and quality of life by disability among people with multiple sclerosis: a register-based study in Sweden. Mult Scler J Exp Transl Clin. 2018;4:2055217318783352.","journal-title":"Mult Scler J Exp Transl Clin"},{"key":"150_CR6","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1177\/1352458517708682","volume":"23","author":"L Brundin","year":"2017","unstructured":"Brundin L, Kobelt G, Berg J, et al. New insights into the burden and costs of multiple sclerosis in Europe: results for Sweden. Mult Scler. 2017;23:179\u201391.","journal-title":"Mult Scler"},{"key":"150_CR7","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1177\/1352458512441566","volume":"18","author":"K Karampampa","year":"2012","unstructured":"Karampampa K, Gustavsson A, Miltenburger C, et al. Treatment experience, burden and unmet needs (TRIBUNE) in MS study: results from five European countries. Mult Scler. 2012;18:7\u201315.","journal-title":"Mult Scler"},{"key":"150_CR8","doi-asserted-by":"publisher","first-page":"918","DOI":"10.1136\/jnnp.2006.090365","volume":"77","author":"G Kobelt","year":"2006","unstructured":"Kobelt G, Berg J, Lindgren P, et al. Costs and quality of life of patients with multiple sclerosis in Europe. J Neurol Neurosurg Psychiatry. 2006;77:918\u201326.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"150_CR9","doi-asserted-by":"crossref","unstructured":"Gyllensten H, Kavaliunas A, Murley C, et al. Costs of illness progression for different multiple sclerosis phenotypes: a population-based study in Sweden. Submitted. 2018.","DOI":"10.1016\/j.jval.2017.08.056"},{"key":"150_CR10","doi-asserted-by":"crossref","unstructured":"Allebeck P, Mastekaasa A. Swedish Council on Technology Assessment in Health Care (SBU). Chapter 5. Risk factors for sick leave\u2014general studies. Scand J Public Health Suppl. 2004;63:49\u2013108.","DOI":"10.1080\/14034950410021853"},{"key":"150_CR11","unstructured":"World Health Organization. International statistical classification of diseases and related health problems 10th revision (ICD-10). Accessed on 12 Dec 2018. \nhttps:\/\/icd.who.int\/browse10\/2016\/en\n\n."},{"key":"150_CR12","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1007\/s10654-016-0117-y","volume":"31","author":"JF Ludvigsson","year":"2016","unstructured":"Ludvigsson JF, Almqvist C, Bonamy AK, et al. Registers of the Swedish total population and their use in medical research. Eur J Epidemiol. 2016;31:125\u201336.","journal-title":"Eur J Epidemiol"},{"key":"150_CR13","volume-title":"Methods for the economic evaluation of health care programmes","author":"MF Drummond","year":"2015","unstructured":"Drummond MF, Sculpher MJ, Claxton K, et al. Methods for the economic evaluation of health care programmes. Oxford: Oxford University Press; 2015."},{"key":"150_CR14","unstructured":"National Insurance Agency [F\u00f6rs\u00e4kringskassan]\u2014Social insurance in figures\u00a02017. \nhttps:\/\/www.forsakringskassan.se\/wps\/wcm\/connect\/6fa0e434-a212-4e6b-8c8d-5d7a498a253d\/socialforsakringen-siffror-2017-engelsk.pdf?MOD=AJPERES&CVID\n\n. Accessed 12 Dec 2018."},{"key":"150_CR15","unstructured":"Eurostat. HICP\u2014all items\u2014annual average indices (2015\u2009=\u2009100). Accessed on December 12, 2018. \nhttps:\/\/ec.europa.eu\/eurostat\/tgm\/table.do?tab=table&init=1&language=en&pcode=tec00027&plugin=1\n\n."},{"key":"150_CR16","doi-asserted-by":"publisher","first-page":"540","DOI":"10.4097\/kjae.2015.68.6.540","volume":"68","author":"TK Kim","year":"2015","unstructured":"Kim TK. T test as a parametric statistic. Korean J Anesthesiol. 2015;68:540\u20136.","journal-title":"Korean J Anesthesiol"},{"key":"150_CR17","doi-asserted-by":"publisher","first-page":"2015","DOI":"10.1177\/0962280216673085","volume":"27","author":"DS Nagin","year":"2018","unstructured":"Nagin DS, Jones BL, Passos VL, et al. Group-based multi-trajectory modeling. Stat Methods Med Res. 2018;27:2015\u201323.","journal-title":"Stat Methods Med Res"},{"key":"150_CR18","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1177\/0049124101029003005","volume":"29","author":"BL Jones","year":"2001","unstructured":"Jones BL, Nagin DS, Roeder K. A SAS procedure based on mixture models for estimating developmental trajectories. Sociol Methods Res. 2001;29:374\u201393.","journal-title":"Sociol Methods Res"},{"key":"150_CR19","volume-title":"Categorical data analysis","author":"A Agresti","year":"2003","unstructured":"Agresti A. Categorical data analysis. New York: John Wiley & Sons; 2003."},{"key":"150_CR20","doi-asserted-by":"publisher","first-page":"e021122","DOI":"10.1136\/bmjopen-2017-021122","volume":"8","author":"NL Pratt","year":"2018","unstructured":"Pratt NL, Kerr M, Barratt JD, et al. The validity of the Rx-risk comorbidity index using medicines mapped to the anatomical therapeutic chemical (ATC) classification system. BMJ Open. 2018;8:e021122.","journal-title":"BMJ Open"},{"key":"150_CR21","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1016\/j.msard.2014.09.002","volume":"3","author":"K O\u2019Connell","year":"2014","unstructured":"O\u2019Connell K, Kelly SB, Fogarty E, et al. Economic costs associated with an MS relapse. Mult Scler Relat Disord. 2014;3:678\u201383.","journal-title":"Mult Scler Relat Disord"},{"key":"150_CR22","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.1177\/1352458517694432","volume":"23","author":"G Kobelt","year":"2017","unstructured":"Kobelt G, Thompson A, Berg J, et al. New insights into the burden and costs of multiple sclerosis in Europe. Mult Scler. 2017;23:1123\u201336.","journal-title":"Mult Scler"},{"key":"150_CR23","doi-asserted-by":"publisher","first-page":"1592","DOI":"10.3390\/ijms17091592","volume":"17","author":"P Schwenkenbecher","year":"2016","unstructured":"Schwenkenbecher P, Sarikidi A, Wurster U, et al. McDonald criteria 2010 and 2005 compared: persistence of high oligoclonal band prevalence despite almost doubled diagnostic sensitivity. Int J Mol Sci. 2016;17:1592.","journal-title":"Int J Mol Sci"},{"key":"150_CR24","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1007\/s10198-017-0894-6","volume":"19","author":"H Gyllensten","year":"2018","unstructured":"Gyllensten H, Wiberg M, Alexanderson K, et al. Costs of illness of multiple sclerosis in Sweden: a population-based register study of people of working age. Eur J Health Econ. 2018;19:435\u201346.","journal-title":"Eur J Health Econ"},{"key":"150_CR25","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/j.msard.2017.11.013","volume":"19","author":"P Rieckmann","year":"2018","unstructured":"Rieckmann P, Centonze D, Elovaara I, et al. Unmet needs, burden of treatment, and patient engagement in multiple sclerosis: a combined perspective from the MS in the 21st century steering group. Mult Scler Relat Disord. 2018;19:153\u201360.","journal-title":"Mult Scler Relat Disord"},{"key":"150_CR26","doi-asserted-by":"publisher","first-page":"1233","DOI":"10.1177\/1352458516675039","volume":"23","author":"A Kavaliunas","year":"2017","unstructured":"Kavaliunas A, Manouchehrinia A, Stawiarz L, et al. Importance of early treatment initiation in the clinical course of multiple sclerosis. Mult Scler. 2017;23:1233\u201340.","journal-title":"Mult Scler."},{"key":"150_CR27","doi-asserted-by":"publisher","first-page":"e104165","DOI":"10.1371\/journal.pone.0104165","volume":"9","author":"P Brenner","year":"2014","unstructured":"Brenner P, Alexanderson K, Bjorkenstam C, et al. Psychiatric diagnoses, medication and risk for disability pension in multiple sclerosis patients; a population-based register study. PLoS One. 2014;9:e104165.","journal-title":"PLoS One"},{"key":"150_CR28","doi-asserted-by":"publisher","first-page":"e012731","DOI":"10.1136\/bmjopen-2016-012731","volume":"6","author":"H Gyllensten","year":"2016","unstructured":"Gyllensten H, Wiberg M, Alexanderson K, et al. How does work disability of patients with MS develop before and after diagnosis? A nationwide cohort study with a reference group. BMJ Open. 2016;6:e012731.","journal-title":"BMJ Open"},{"key":"150_CR29","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1186\/1471-2458-11-450","volume":"11","author":"JF Ludvigsson","year":"2011","unstructured":"Ludvigsson JF, Andersson E, Ekbom A, et al. External review and validation of the Swedish national inpatient register. BMC Public Health. 2011;11:450.","journal-title":"BMC Public Health"},{"key":"150_CR30","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1111\/bcpt.12613","volume":"119","author":"SM Wallerstedt","year":"2016","unstructured":"Wallerstedt SM, Wettermark B, Hoffmann M. The first decade with the Swedish Prescribed Drug Register\u2014a systematic review of the output in the scientific literature. Basic Clin Pharmacol Toxicol. 2016;119:464\u20139.","journal-title":"Basic Clin Pharmacol Toxicol"},{"key":"150_CR31","unstructured":"Swedish Association of Local Authorities and Regions [Sveriges Kommuner och Landsting]\u2014KPP Somatik. \nhttps:\/\/skl.se\/ekonomijuridikstatistik\/statistik\/kostnadperpatientkpp\/kppsomatik.1077.html\n\n. Accessed 12 Dec 2018."},{"key":"150_CR32","unstructured":"1177 V\u00e5rdguiden\u2014Patient fees in V\u00e4stra G\u00f6taland county in Sweden [Patientavgifter i V\u00e4stra G\u00f6taland]. \nhttps:\/\/www.1177.se\/Vastra-Gotaland\/Regler-och-rattigheter\/Patientavgifter-i-Vastra-Gotaland\/\n\n. Accessed 12 Dec 2018."},{"key":"150_CR33","unstructured":"Swedish Association of Local Authorities and Regions [Sveriges Kommuner och Landsting]\u2014Patientavgifter fr.o.m. den 1 januari 2018. \nhttps:\/\/skl.se\/download\/18.3ee4cc4f1611af77b89179dd\/1517495154691\/avgift_%C3%B6ppenv%C3%A5rd_inkl.missiv_slutenavg18_19jan18.pdf\n\n. Accessed 12 Dec 2018."},{"key":"150_CR34","unstructured":"Swedish Association of Local Authorities and Regions [Sveriges Komuner och Landsting]\u2013Patientavgifter i h\u00e4lso- och sjukv\u00e5rden 2018. \nhttps:\/\/skl.se\/halsasjukvard\/patientinflytande\/patientavgifter.14668.html\n\n. Accessed 12 Dec 2018."},{"key":"150_CR35","unstructured":"Statistics Sweden. Genomsnittlig m\u00e5nadsl\u00f6n, l\u00f6n i fasta priser och l\u00f6nespridning efter yrkesgrupp (SSYK 96) och k\u00f6n. \u00c5r 1996\u20132013-Statistikdatabasen. Accessed on 12 Dec 2018. \nhttp:\/\/www.statistikdatabasen.scb.se\/pxweb\/sv\/ssd\/START__AM__AM0112\/TidsserieYrke\/\n\n."},{"key":"150_CR36","unstructured":"Swedish Tax Authority [Skatteverket]. Belopp och procent f\u00f6r \u00e5ren 2014\u20132004\u2013privat. Accessed on 12 Decr 2018. \nhttps:\/\/www.skatteverket.se\/privat\/skatter\/beloppochprocent\/tidigarear.4.1a098b721295c544e1f800018171.html\n\n."},{"key":"150_CR37","unstructured":"Eurostat. Annual exchange rates (ECU\/EUR exchange rates versus national currencies). Accessed on 12 December 2018. \nhttps:\/\/ec.europa.eu\/eurostat\/tgm\/table.do?tab=table&init=1&language=en&pcode=tec00033&plugin=1\n\n."}],"container-title":["PharmacoEconomics - Open"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s41669-019-0150-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s41669-019-0150-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s41669-019-0150-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,6,9]],"date-time":"2020-06-09T23:12:43Z","timestamp":1591744363000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s41669-019-0150-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,6,11]]},"references-count":37,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,3]]}},"alternative-id":["150"],"URL":"https:\/\/doi.org\/10.1007\/s41669-019-0150-3","relation":{},"ISSN":["2509-4262","2509-4254"],"issn-type":[{"value":"2509-4262","type":"print"},{"value":"2509-4254","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,6,11]]},"assertion":[{"value":"11 June 2019","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"All authors (KK, HG, FY, CM, EF, JH, and KA) have received funding from an unrestricted investigator-initiated trial grant from Biogen to support the conduct of this study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"All authors (KK, HG, FY, CM, EF, JH, and KA) are employed at or affiliated with the Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden. FY is currently employed by PPD Scandinavia AB, and HG is currently employed part-time by Statfinn\/EPID Research (which is part of IQVIA); both companies are contract research organisations that perform commissioned pharmacoepidemiological studies and, therefore, are collaborating with several pharmaceutical companies.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}